Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 190 entries
Sorted by: Best Match Show Resources per page
5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.

The Canadian journal of hospital pharmacy

Jun JEJ, Kinkade A, Tung ACH, Tejani AM.
PMID: 28487578
Can J Hosp Pharm. 2017 Mar-Apr;70(2):113-119. doi: 10.4212/cjhp.v70i2.1643. Epub 2017 Apr 28.

BACKGROUND: Finasteride and dutasteride are competitive inhibitors of 5α-reductase enzymes and are commonly used to treat symptomatic benign prostatic hyperplasia (BPH).OBJECTIVE: To compare the efficacy and safety of finasteride and dutasteride in terms of clinically important outcomes.DATA SOURCES: A...

Cite
Jun JEJ, Kinkade A, Tung ACH, et al. 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. Can J Hosp Pharm. 2017;70(2):113-119doi: 10.4212/cjhp.v70i2.1643.
Jun, J. E. J., Kinkade, A., Tung, A. C. H., & Tejani, A. M. (2017). 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. The Canadian journal of hospital pharmacy, 70(2), 113-119. https://doi.org/10.4212/cjhp.v70i2.1643
Jun, Jennifer E J, et al. "5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis." The Canadian journal of hospital pharmacy vol. 70,2 (2017): 113-119. doi: https://doi.org/10.4212/cjhp.v70i2.1643
Jun JEJ, Kinkade A, Tung ACH, Tejani AM. 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. Can J Hosp Pharm. 2017 Mar-Apr;70(2):113-119. doi: 10.4212/cjhp.v70i2.1643. Epub 2017 Apr 28. PMID: 28487578; PMCID: PMC5407420.
Copy Download .nbib Format: NLM
Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers.

Journal of drug assessment

Fossler MJ, Collins DA, Ino H, Sarai N, Ravindranath R, Bowen CL, Burns O.
PMID: 27536459
J Drug Assess. 2015 Jul 14;4(1):24-9. doi: 10.3109/21556660.2015.1067219. eCollection 2015.

OBJECTIVE: To evaluate the bioequivalence of five 0.1 mg dutasteride capsules to one 0.5 mg dutasteride capsule in healthy adult male subjects under fasting conditions.METHODS: This was a single-center, open-label, randomized, single dose, two-way cross-over study (ClinicalTrials.gov identifier NCT01929330)....

Cite
Fossler MJ, Collins DA, Ino H, et al. Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers. J Drug Assess. 2015;4(1):24-9doi: 10.3109/21556660.2015.1067219.
Fossler, M. J., Collins, D. A., Ino, H., Sarai, N., Ravindranath, R., Bowen, C. L., & Burns, O. (2015). Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers. Journal of drug assessment, 4(1), 24-9. https://doi.org/10.3109/21556660.2015.1067219
Fossler, Michael J, et al. "Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers." Journal of drug assessment vol. 4,1 (2015): 24-9. doi: https://doi.org/10.3109/21556660.2015.1067219
Fossler MJ, Collins DA, Ino H, Sarai N, Ravindranath R, Bowen CL, Burns O. Evaluation of bioequivalence of five 0.1 mg dutasteride capsules compared to one 0.5 mg dutasteride capsule: a randomized study in healthy male volunteers. J Drug Assess. 2015 Jul 14;4(1):24-9. doi: 10.3109/21556660.2015.1067219. eCollection 2015. PMID: 27536459; PMCID: PMC4937626.
Copy Download .nbib Format: NLM
Finasteride-mediated hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia.

JAAD case reports

Donovan JC.
PMID: 27051778
JAAD Case Rep. 2015 Sep 30;1(6):353-5. doi: 10.1016/j.jdcr.2015.08.003. eCollection 2015 Nov.

No abstract available.

Cite
Donovan JC. Finasteride-mediated hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia. JAAD Case Rep. 2015;1(6):353-5doi: 10.1016/j.jdcr.2015.08.003.
Donovan, J. C. (2015). Finasteride-mediated hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia. JAAD case reports, 1(6), 353-5. https://doi.org/10.1016/j.jdcr.2015.08.003
Donovan, Jeff C. "Finasteride-mediated hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia." JAAD case reports vol. 1,6 (2015): 353-5. doi: https://doi.org/10.1016/j.jdcr.2015.08.003
Donovan JC. Finasteride-mediated hair regrowth and reversal of atrophy in a patient with frontal fibrosing alopecia. JAAD Case Rep. 2015 Sep 30;1(6):353-5. doi: 10.1016/j.jdcr.2015.08.003. eCollection 2015 Nov. PMID: 27051778; PMCID: PMC4809380.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 12616965
Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(10):703-29
Bayés, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(10), 703-29.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,10 (2002): 703-29.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29. PMID: 12616965.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 18985183
Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88.

Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008;30(7):543-88
Tomillero, A., & Moral, M. A. (2008). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 30(7), 543-88.
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 30,7 (2008): 543-88.
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88. PMID: 18985183.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 16082422
Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(5):331-72
Bayés, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(5), 331-72.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,5 (2005): 331-72.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. PMID: 16082422.
Copy Download .nbib Format: NLM
5alpha-reductase: history and clinical importance.

Reviews in urology

Marks LS.
PMID: 16985920
Rev Urol. 2004;6:S11-21.

The treatment of men with symptomatic benign prostatic hyperplasia (BPH) has shifted dramatically from surgery to drug therapy over the past decade. The revolution in BPH treatment began with the discovery of congenital 5alpha-reductase (5AR) deficiency, leading to the...

Cite
Marks LS. 5alpha-reductase: history and clinical importance. Rev Urol. 2004;6:S11-21
Marks, L. S. (2004). 5alpha-reductase: history and clinical importance. Reviews in urology, 6S11-21.
Marks, Leonard S. "5alpha-reductase: history and clinical importance." Reviews in urology vol. 6 (2004): S11-21.
Marks LS. 5alpha-reductase: history and clinical importance. Rev Urol. 2004;6:S11-21. PMID: 16985920; PMCID: PMC1472916.
Copy Download .nbib Format: NLM
[Efficacy of dutasteride, alfuzosin or both on Quality of Life in patients with prostatic hyperplasia and BOO.A two-year spontaneous, observational, self-controlled study].

Urologia

Ventimiglia B, Consoli S, Serrao M, Tsirgiotis A.
PMID: 21086358
Urologia. 2008 Apr-Jun;75(1):97-101.

Three homogeneous groups of patients suffering from benign prostatic hypertrophy (BPH) were evaluated by means of a two-year observational study, in order to assess and compare their Quality of Life (QoL) under the following different medical treatments. Group 1:...

Cite
Ventimiglia B, Consoli S, Serrao M, et al. [Efficacy of dutasteride, alfuzosin or both on Quality of Life in patients with prostatic hyperplasia and BOO.A two-year spontaneous, observational, self-controlled study]. Urologia. 2008;75(1):97-101
Ventimiglia, B., Consoli, S., Serrao, M., & Tsirgiotis, A. (2008). [Efficacy of dutasteride, alfuzosin or both on Quality of Life in patients with prostatic hyperplasia and BOO.A two-year spontaneous, observational, self-controlled study]. Urologia, 75(1), 97-101.
Ventimiglia, B, et al. "[Efficacy of dutasteride, alfuzosin or both on Quality of Life in patients with prostatic hyperplasia and BOO.A two-year spontaneous, observational, self-controlled study]." Urologia vol. 75,1 (2008): 97-101.
Ventimiglia B, Consoli S, Serrao M, Tsirgiotis A. [Efficacy of dutasteride, alfuzosin or both on Quality of Life in patients with prostatic hyperplasia and BOO.A two-year spontaneous, observational, self-controlled study]. Urologia. 2008 Apr-Jun;75(1):97-101. Italian. PMID: 21086358.
Copy Download .nbib Format: NLM
Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells.

International journal of clinical and experimental medicine

Alisky JM, Tang Y, Habermehl GK, Iczkowski KA.
PMID: 20827322
Int J Clin Exp Med. 2010 Jul 25;3(3):245-7.

We show that the dual 5-α reductase enzyme inhibitor dutasteride prevents enhanced growth of both benign and malignant prostate cell lines, incubated with physiologic to supraphysiologic doses of testosterone. Using androgen-sensitive benign BPH-1 cells, LNCaP cancer cells, their derivative...

Cite
Alisky JM, Tang Y, Habermehl GK, et al. Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells. Int J Clin Exp Med. 2010;3(3):245-7
Alisky, J. M., Tang, Y., Habermehl, G. K., & Iczkowski, K. A. (2010). Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells. International journal of clinical and experimental medicine, 3(3), 245-7.
Alisky, Joseph M, et al. "Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells." International journal of clinical and experimental medicine vol. 3,3 (2010): 245-7.
Alisky JM, Tang Y, Habermehl GK, Iczkowski KA. Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells. Int J Clin Exp Med. 2010 Jul 25;3(3):245-7. PMID: 20827322; PMCID: PMC2929950.
Copy Download .nbib Format: NLM
Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole G, Bostwick D, Brawley O, et al. N Engl J Med 2010;362:1192-202.

European urology

Klotz L.
PMID: 20845544
Eur Urol. 2010 Aug;58(2):313. doi: 10.1016/j.eururo.2010.05.017.

This is the first published report of the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial, a 4-yr, multicenter, randomized, double-blind, placebo-controlled study involving 6729 men and comparing dutasteride 0.5 mg daily to placebo. The study was similar...

Cite
Klotz L. Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole G, Bostwick D, Brawley O, et al. N Engl J Med 2010;362:1192-202. Eur Urol. 2010;58(2):313doi: 10.1016/j.eururo.2010.05.017.
Klotz, L. (2010). Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole G, Bostwick D, Brawley O, et al. N Engl J Med 2010;362:1192-202. European urology, 58(2), 313. https://doi.org/10.1016/j.eururo.2010.05.017
Klotz, Laurence. "Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole G, Bostwick D, Brawley O, et al. N Engl J Med 2010;362:1192-202." European urology vol. 58,2 (2010): 313. doi: https://doi.org/10.1016/j.eururo.2010.05.017
Klotz L. Words of wisdom. Re: Effect of dutasteride on the risk of prostate cancer. Andriole G, Bostwick D, Brawley O, et al. N Engl J Med 2010;362:1192-202. Eur Urol. 2010 Aug;58(2):313. doi: 10.1016/j.eururo.2010.05.017. PMID: 20845544.
Copy Download .nbib Format: NLM
Dutasteride reduces incident prostate cancer in men after negative prostate biopsy.

Evidence-based medicine

Vickers A.
PMID: 20530608
Evid Based Med. 2010 Aug;15(4):119-20. doi: 10.1136/ebm1082. Epub 2010 Jun 08.

No abstract available.

Cite
Vickers A. Dutasteride reduces incident prostate cancer in men after negative prostate biopsy. Evid Based Med. 2010;15(4):119-20doi: 10.1136/ebm1082.
Vickers, A. (2010). Dutasteride reduces incident prostate cancer in men after negative prostate biopsy. Evidence-based medicine, 15(4), 119-20. https://doi.org/10.1136/ebm1082
Vickers, Andrew. "Dutasteride reduces incident prostate cancer in men after negative prostate biopsy." Evidence-based medicine vol. 15,4 (2010): 119-20. doi: https://doi.org/10.1136/ebm1082
Vickers A. Dutasteride reduces incident prostate cancer in men after negative prostate biopsy. Evid Based Med. 2010 Aug;15(4):119-20. doi: 10.1136/ebm1082. Epub 2010 Jun 08. PMID: 20530608.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayes M, Rabasseda X, Prous JR.
PMID: 16082427
Methods Find Exp Clin Pharmacol. 2005 May;27(4):265-84.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(4):265-84
Bayes, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(4), 265-84.
Bayes, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,4 (2005): 265-84.
Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 May;27(4):265-84. PMID: 16082427.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 190 entries